A Canadian technology that could outsmart cancer has scored a major investment from Roche, a pharmaceutical giant with more than 600 employees in Canada and over 90,000 globally. The licensing deal worth up to US$140 million is the largest ever made by the University of British Columbia, and much of the credit goes to PC-TRiADD – the commercialization arm of the Vancouver Prostate Centre. PC-TRiADD applied its business acumen to the scientific process to identify the most promising technologies, protect the intellectual property (IP) and generate the scientific data required to support IP claims and generate regulatory submissions to Health Canada.The new drug candidate outsmarts cancer by attacking the same male hormone (androgen) receptor that promotes tumour growth. The goal is to have a simple pill that prostate cancer patients can take daily.